[Determination of antithrombin III (chromogenic substrates) and FDP in women in treatment with oral estroprogestin agents].
In 280 women, in fertile age, 133 of whom represented the control group, FDP and antithrombin III with the method of chromogenic substrates were determined. In 147 women, who were taking, for variable period of time, oral estroprogestinic drugs, a significant diminution of antithrombin III was found. No significant differences for FDP were observed.
D000293:Adolescent; D000328:Adult; D000813:Anilides; D000991:Antithrombins / Q000032:analysis*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D006801:Humans; D008656:Mestranol / Q000494:pharmacology; D008875:Middle Aged; D009842:Oligopeptides; D045167:Progesterone Congeners / Q000494:pharmacology*
D000813:Anilides; D000991:Antithrombins; D005338:Fibrin Fibrinogen Degradation Products; D009842:Oligopeptides; D045167:Progesterone Congeners; D008656:Mestranol
Valutazione dell'antitrombina III (substrati cromogeni) e FDP in donne in trattamento con estroprogestinici orali.